Literature DB >> 16043787

Association between benign and malignant peripheral nerve sheath tumors in NF1.

T Tucker1, P Wolkenstein, J Revuz, J Zeller, J M Friedman.   

Abstract

OBJECTIVE: People with neurofibromatosis type 1 (NF1) have a 10% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST). MPNSTs are often metastatic and are a frequent cause of death among people with NF1. Clinical evidence suggests that most MPNSTs in people with NF1 develop from preexisting plexiform neurofibromas. However, it is not known whether an individual's risk of developing an MPNST is associated with the burden of benign neurofibromas. The authors conducted a study to determine whether people with NF1 who have benign neurofibromas of various kinds are at greater risk of developing MPNSTs than patients with NF1 who lack these benign tumors.
METHODS: Clinical information on 476 NF1 probands in the Henri Mondor Database was analyzed by logistic regression to examine associations between MPNSTs and internal plexiform, superficial plexiform, subcutaneous, and cutaneous neurofibromas.
RESULTS: Individuals with subcutaneous neurofibromas were approximately three times more likely to have internal plexiform neurofibromas or MPNSTs than individuals without subcutaneous neurofibromas. Individuals with internal plexiform neurofibromas were 20 times more likely to have MPNSTs than individuals without internal plexiform neurofibromas. When this analysis was done with both subcutaneous and internal plexiform neurofibromas as explanatory variables, only the association of MPNSTs with internal plexiform neurofibromas remained significant.
CONCLUSIONS: The observation that malignant peripheral nerve sheath tumors are strongly associated with internal plexiform neurofibromas suggests that patients with neurofibromatosis type 1 with these benign tumors warrant increased surveillance for malignancy.

Entities:  

Mesh:

Year:  2005        PMID: 16043787     DOI: 10.1212/01.wnl.0000168830.79997.13

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  70 in total

1.  [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.

Authors:  L L Tsai; L Drubach; F Fahey; M Irons; S Voss; N J Ullrich
Journal:  J Neurooncol       Date:  2012-03-11       Impact factor: 4.130

2.  Early-stage malignant peripheral nerve sheath tumour arising from a solitary neurofibroma.

Authors:  T Hyodo; Y Sugawara; K Sakayama; K Kito
Journal:  Br J Radiol       Date:  2012-02       Impact factor: 3.039

3.  Perioperative management of neurofibromatosis type 1.

Authors:  Charles J Fox; Samir Tomajian; Aaron J Kaye; Stephanie Russo; Jacqueline Volpi Abadie; Alan D Kaye
Journal:  Ochsner J       Date:  2012

Review 4.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

Review 5.  Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Authors:  Brigitte C Widemann
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

6.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

7.  Neurofibromatosis type 1: focal dystonia associated with a malignant peripheral nerve sheath tumour-a video-illustrated case.

Authors:  Teresa Sequeira; João Nuno Oliveira; Ana Ramos Sequeira; Sara M Rocha
Journal:  BMJ Case Rep       Date:  2016-10-20

8.  18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.

Authors:  Johannes Salamon; Simon Veldhoen; Ivayla Apostolova; Peter Bannas; Jin Yamamura; Jochen Herrmann; Reinhard E Friedrich; Gerhard Adam; Victor F Mautner; Thorsten Derlin
Journal:  Eur Radiol       Date:  2013-10-05       Impact factor: 5.315

Review 9.  NF1 diagnosis criteria and associated sarcomatous tumor review of the literature and case report.

Authors:  Márcia Gaiger de Oliveira; Sabrina Pozatti Moure; Paulo Sérgio Batista; Anna Cecília Moraes Chaves; Pantelis V Rados; Manoel Sant'Ana Filho
Journal:  Oral Maxillofac Surg       Date:  2008-12

10.  Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.

Authors:  Markus P Ghadimi; Gonzalo Lopez; Keila E Torres; Roman Belousov; Eric D Young; Jeffery Liu; Kari J Brewer; Aviad Hoffman; Kristelle Lusby; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.